BSPRY inhibitors encompass a chemical class that targets cellular processes and signaling pathways associated with the BSPRY protein. Inhibitors in this class are not specific to the BSPRY protein itself but instead modulate the activity of various enzymes and cellular components that, in turn, influence the biological context in which BSPRY operates. For instance, MAP kinase inhibitors can alter the MAPK pathway, which is a key regulator of cell division, differentiation, and response to stress signals. These inhibitors can, therefore, modulate the function of proteins like BSPRY that are associated with these cellular processes.
The chemical class also includes compounds that inhibit kinases such as MEK, which are part of the ERK pathway. This pathway plays a role in cell cycle control and differentiation, potentially affecting the cellular roles of BSPRY. PI3K inhibitors impact cellular processes such as cell growth and survival, which are also areas where BSPRY may have a role. Other compounds can impact cell growth and metabolism, providing a means by which BSPRY-associated processes could be influenced. Proteasome and histone deacetylase inhibitors affect protein degradation and gene expression, which could impact the stability and function of proteins including BSPRY. Lastly, other groups of inhibitors affect NF-κB signaling, T-cell activation, and calcium signaling, all of which are processes that can intersect with BSPRY's role in the cell. By affecting these upstream pathways and processes, these inhibitors can indirectly modify the activity or context of the BSPRY protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase, which is part of the MAPK signaling pathway that can modulate the activity of proteins including BSPRY. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that affects the PI3K/Akt pathway, potentially altering BSPRY-associated cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An MEK inhibitor, which may affect the ERK pathway and consequently the role of BSPRY in signal transduction. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which could modify BSPRY activity due to its involvement in the MAPK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A broad-spectrum PI3K inhibitor that can alter signaling pathways and processes involving BSPRY. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Specifically inhibits mTOR, which is connected to cellular growth processes that BSPRY may be a part of. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor that can affect gene expression and protein interactions, potentially impacting BSPRY functions. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that can affect protein degradation pathways, possibly influencing BSPRY stability. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Inhibits NF-κB activation, which can modulate inflammatory signaling pathways that BSPRY may be involved in. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Inhibits calcineurin, thereby affecting T-cell activation and signaling that BSPRY could be implicated in. |